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A lthough treatment strategies for hepatocellular carcinoma (HCC) have greatly improved,  the 
prognosis remains poor.  In most cases,  HCC develops 
in patients with chronic hepatitis or liver cirrhosis (LC) 
— conditions that are characterized by persistent hepatic 
injury and concurrent liver regeneration.  Chronic 
inflammation causes the accumulation of genetic and 
epigenetic changes in hepatocytes,  resulting in the 
development of hepatocellular carcinoma.  Despite 
advances in this area,  the molecular pathogenesis of 
HCC is poorly understood.  Different studies have 
reported different sets of genes that are frequently 
altered in patients with HCC.  Nonetheless,  changes in 
Wnt pathway-associated genes in HCC are clearly among 
the major gene alterations,  and a molecule related to 
Wnt signaling has been shown to exhibit anti-cancer 
activity against HCC [1].  
The reduced expression in immortalized cells 
(REIC)/Dickkopf-3 (Dkk-3) gene was identified as a 
tumor suppressor gene,  and is downregulated in various 
cancers [2].  Overexpression of the REIC/Dkk-3 gene 
induces endoplasmic reticulum stress,  which is respon-
sible for apoptosis through the c-Jun-NH2-kinase path-
way in cancer cells [2].  The REIC/Dkk-3 gene expression 
is decreased or lost in various cancers,  including hepa-
tocellular carcinoma [3-7],  and the adenovirus-medi-
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The physiological role of the reduced expression of immortalized cells (REIC)/Dickkopf-3 (Dkk-3) protein in 
patients with hepatocellular carcinoma (HCC) remains unclear.  In this study,  we evaluated the effect of the 
REIC/Dkk-3 protein on HCC cell proliferation and assessed the relationship between the serum REIC/Dkk-3 
protein level and the prognosis in patients with HCC.  We evaluated the REIC/Dkk-3 protein-induced antican-
cer effects on Huh7 and Hep3B cells (HCC cell lines) in the presence of peripheral blood mononuclear cells 
(PBMCs),  and found that combination treatment with REIC/Dkk-3 protein and PBMCs reduced the prolifera-
tion of HCC cells (Hep3B: 82.0% ± 16.3%; Huh7: 72.6% ± 9.1%).  We also studied 194 HCC patients who 
underwent primary liver resection or primary radiofrequency ablation from 2008 to 2017.  Serum REIC/Dkk-3 
protein levels were measured by an enzyme-linked immunosorbent assay and compared to the prognostic data.  
The 3-year disease-free survival of the REIC/Dkk-3 high group was significantly higher than that in the REIC/
Dkk-3 low group.  In conclusion,  this is the first study investigating the relationship between HCC patient sur-
vival and serum REIC/Dkk-3 protein levels in a large population.  Based on the results,  the serum REIC/Dkk-3 
protein level should be considered a new prognostic marker for patients with HCC.
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ated overexpression of REIC/Dkk-3 induces cancer cell 
death.  The REIC/Dkk-3 gene was found to be consistent 
with the human Dkk-3 gene and belongs to the Dkk 
protein family.  Dkk-3 is a 350 amino acid secreted gly-
coprotein,  which is comprised of an N-terminal signal 
peptide and 2 conserved cysteine-rich domains that are 
divided by 12 amino acid linker regions [8].  The func-
tion of REIC/Dkk-3 under normal physiological condi-
tions is still unknown.  A Dkk-3 knockout mouse study 
revealed no major alterations in their phenotype [9].  
Cancer cells are thought to evade immune surveil-
lance by disabling the immune system function of CD8+  
cytotoxic T lymphocytes (CTL) and natural killer (NK) 
cells [10].  Although some studies have reported that 
REIC/Dkk-3 functions in the regulation of anti-tumor 
immune responses,  we and others reported that REIC/
Dkk-3 actually activated an anti-tumor immune 
response [11-13].  In addition,  in peripheral blood 
mononuclear cells (PBMCs),  it was reported that the 
REIC/Dkk-3 protein upregulated the differentiation of 
monocytes to a dendritic cell (DC)-like phenotype and 
subsequently activated the CTL function [14-16].  It is 
possible that this immune-stimulatory mechanism is 
related to the recognition of major histocompatibility 
complex class I-presented tumor antigens between DCs 
and CTLs [14].  In our previous study,  we evaluated the 
REIC/Dkk-3 protein-induced immunological antitu-
mor effects on pancreatic cancer cells in vivo and in vitro 
when pancreatic cells were co-cultured with PBMCs,  in 
order to elucidate the synergistic immunological effects 
of REIC/Dkk-3 protein and PBMCs [17].  We thus con-
sidered it would be useful to examine whether the REIC 
protein induces an antitumor effect in HCC cell lines.  
In the present study,  therefore,  we evaluated the REIC/
Dkk-3 protein-induced immunological antitumor 
effects on HCC cells and retrospectively examined the 
serum REIC/Dkk-3 levels in HCC patients.  
Materials and Methods
Assessment of immunological effects on HCC cells in 
vitro
1.  Cell lines and cell culture
The Huh7 HCC cell line was obtained from the 
Japanese Cancer Resources Bank (Tokyo),  and the 
Hep3B cell line was obtained from DS Pharma 
Biomedical (Osaka,  Japan).  Each of the cell lines were 
maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen,  Carlsbad,  CA,  USA),  which was supple-
mented with 10% heat-inactivated fetal bovine serum 
(FBS) (Sigma-Aldrich Japan,  Tokyo),  1% non-essential 
amino acids (Sigma),  1% penicillin/streptomycin solu-
tion (Sigma),  and amphotericin B (0.5 μg/mL).  The 
cells were cultured at 37°C in a humidified atmosphere 
of 5% CO2 and 95% air and were made quiescent at 
subconfluence under restricted serum conditions with 
0.1% dialyzed FBS for 24 h before the experiment.  
PBMCs were obtained from Lonza (Tokyo).
2.  Human REIC/Dkk-3 protein
Human REIC/Dkk-3 protein [18] was obtained from 
the Innovation Center Okayama for Nano-bio-targeted 
Therapy,  Okayama University.  Stock solutions of 
REIC/Dkk-3 protein were maintained at -80°C until use.
3.  Assessment of lymphocyte cytotoxicity
Huh7 and Hep3B cells (5.0 × 104 cells/well) were 
seeded in flat-bottomed 6-well plates,  and co-cultured 
with or without PBMCs (5.0 × 105 cells/well) in the 
absence or presence of REIC/Dkk3 protein (10 µg/ml).  
After 5 days of incubation,  cell viability was evaluated 
using a methyl thiazole tetrazolium (MTT) assay.  
PBMCs were removed by washing twice with cold 
phosphate-buffered saline before the MTT assay.  
Examination of the impact of serum REIC/Dkk-3 
protein in HCC patients
1.  Patients
A total of 194 HCC patients who were treated at 
Okayama University Hospital were recruited.  We retro-
spectively studied HCC patients who underwent pri-
mary liver resection or primary radiofrequency ablation 
for HCC admitted to our unit from February 2008 to 
January 2017.  The average observation time was 
1441 days.  All patient serums were gathered before 
therapy.  The subjects included HBV-positive (n = 70),  
HCV-positive (n = 70) and HBV/HCV-negative (n = 54) 
patients.  The diagnosis of HCC was made based on 
vascularization,  which was detected on dynamic com-
puted tomography (CT) or magnetic resonance imaging 
(MRI) after contrast enhancement.  The diagnosis of 
HCC was confirmed by CT,  MRI,  or biopsy results.  
The study protocol was reviewed and approved by the 
Ethics Committee of the Okayama University (approval 
number: ken1703-048).  Written informed consent was 
obtained from the subjects.  The major characteristics of 
the study subjects are summarized in Table 1.
2.  Enzyme-linked immunosorbent assay (ELISA)
Peripheral blood samples were collected before sur-
238 Oyama et al. Acta Med.  Okayama　Vol.  74,  No.  3
gery or radio frequency ablation (RFA).   Samples were 
centrifuged for 5 min at 540 × g and separated into 
plasma and serum.  The serums were stored at -20°C 
until use.  The serum REIC/Dkk-3 protein levels were 
measured using a commercially available enzyme-
linked immunosorbent assay kit (R&D Systems,  
Minneapolis,  MN) according to the manufacturer’s 
protocol.  The optical density was measured at 450 nm 
and referenced to 570 nm on a MultiskanTM GO micro-
plate spectrophotometer (Thermo Fisher Scientific Inc.,  
Waltham,  MA,  USA).  The REIC/Dkk-3 concentra-
tions were obtained with a 2-parameter logistic curve 
fitted against a standard curve and multiplied by the 
dilution factor.
Statistical analyses
The results were analyzed using the Mann-Whitney 
U-test and Student’s t-test.  The JMP12 software program 
(SAS Institute Japan,  Tokyo) was used to perform the 
statistical analyses.  A Kaplan-Meier survival analysis 
was performed to obtain the survival curves.  The log-
rank test was used to compare survival between the high 
and low REIC/Dkk-3 protein level groups.  The dura-
tion of disease-free survival was determined from the 
day following surgery or RFA to the day that initial 
recurrence or metastasis was detected by a clinical 
examination.  Overall survival was calculated from the 
day following surgery or RFA to the last follow-up 
appointment.  The data are presented as the mean ±  
standard deviation (SD).  p-values of < 0.05 were consid-
ered to indicate statistical significance.
Results
Combined therapy with REIC/Dkk-3 protein and 
PBMCs induces antitumor effects. REIC/Dkk-3 pro-
tein slightly reduced the proliferation of HCC cells 
(Hep3B: 96.9% ± 12.9%; Huh7: 94.2% ± 2. 8%); this 
effect was greater when the cells were co-cultured with 
PBMCs (Hep3B: 82.0% ± 16.3%; Huh7: 72.6% ± 9.1%) 
(Fig. 1).  
The presence of REIC/Dkk-3 proteins in serum 
samples of HCC patients. The clinical background of 
the study patients is shown in Table 1.  The rates of 
3-year disease-free and overall survival were 42.7% and 
82.4%,  respectively (Fig. 2a , b).  The 194 HCC patients 
enrolled in the present study were divided into two 
groups according to the mean serum REIC/Dkk-3 pro-
tein level (16741 pg/mL; determined by ELISA): the 
REIC/Dkk-3 high group (> 16741 pg/mL; n = 97) and 
the REIC/Dkk-3 low group (≤ 16741 pg/mL; n = 97).  
There were no significant differences between the 
REIC/Dkk-3 high and REIC/Dkk-3 low groups with 
regard to age,  sex,  HBV infection,  HCV infection,  
alcohol consumption,  TNM stage or Child-Pugh grade 
(Table 2).  Figure 2 shows the differences in survival 
according to the serum REIC/Dkk-3 level.  The 3-year 
disease-free survival rates of the REIC/Dkk-3 high and 
REIC/Dkk-3 low groups were 49.0% and 35.1%,  
respectively (Fig. 2a).  The serum REIC/Dkk-3 level sig-
nificantly affected disease-free survival (p = 0.04).  The 
3-year overall survival rates of the REIC/Dkk-3 high 
and REIC/Dkk-3 low groups were 84.1% and 80.1%,  
respectively (Fig. 2b).  Although the difference was not 
statistically significant (p = 0.08),  the REIC/Dkk-3 high 
group showed a more favorable prognosis.  
Discussion
The REIC/Dkk-3 gene was isolated and cloned as an 
immortalization-related gene at Okayama University in 
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Table 1　 The major characteristics of the patients
Parameters †: median (range) n=194
Age† 70.5 (38-87)
Sex (male: female) 138 (71%): 56 (29%)
HBs Ag (＋) 40 (21%)
HCV Ab (＋) 122 (63%)
Alcohol consumption†(g) 10 (0-310)
Stage ( I/ II/ III/ IV) 94 (48%)/78 (40%)/18 (9%)/4 (2%)
Tumor size,  mm† 15.5 (6-105)
Multiple tumors 53 (27%)
Child Pugh grade (A/B/C) 180/13/1
Serum REIC/Dkk-3 protein,  pg/mL† 16741 (2642-33281)




Fig. 2　 Disease-free survival and overall survival in the study population.  A Kaplan-Meier analysis was performed to investigate the 
relationships between the serum REIC/Dkk-3 protein levels and disease-free survival (A) and overall survival (B).  The dotted line indicates 
the 3-year survival rate.  In both figures,  the Kaplan-Meier curve of all patients (left) and those of the REIC/Dkk-3 high and low groups 
(right) are shown separately.  ＊p<0.05.
＊＊p <0.01
Fig. 1　 Cell viability induced by REIC/Dkk-3 protein.  Hep3B and Huh7 cells were co-cultured with or without PBMCs for 5 days in the 
absence or presence of REIC/Dkk-3 protein.  Cell viability was evaluated using an MTT assay.  The results are presented as the mean±
standard deviation (n=21).  ＊＊p<0.01.
2000 and identified as a new tumor suppressor gene [2].  
REIC/Dkk-3 gene therapy was demonstrated to induce 
immunological effects in several studies as well as can-
cer cell apoptosis in a prostate cancer study [19-21].  
The aberrant expression of Wnt or the downregulation 
of Wnt antagonists has repeatedly been reported in sev-
eral types of malignancy [1].  The degree of REIC/Dkk-3 
methylation in the tissues of HCC patients is higher 
than that in the tissues of cirrhosis patients without 
HCC [22].  Moreover,  high levels of REIC/Dkk-3 gene 
methylation are associated with a poor prognosis in 
HCC [22].  Thus,  it is possible that REIC/Dkk-3 may 
function as a tumor suppressor gene in HCC.  Dkk-3 has 
been found to be overexpressed in hepatoblastoma and 
HCC,  suggesting that the function of REIC/Dkk-3 may 
differ according to the tissue of origin [23].  
We previously demonstrated that the REIC/Dkk-3 
protein reduced pancreatic cancer cell proliferation by 
inducing cytotoxic effects in the presence of PBMCs 
[17].  Moreover,  it was demonstrated that recombinant 
REIC/Dkk-3 protein induced the differentiation of 
monocytes into a DC-like phenotype,  and that immu-
nological activation appears to play an important role in 
tumor antigen presentation to CTL cells.  The REIC/
Dkk-3 protein may be the key mediator of antitumor 
immunity via the induction of monocyte differentia-
tion.  Therefore,  in the present study we conducted an 
experiment to evaluate the effect of purified REIC/
Dkk-3 protein on HCC cell proliferation in the presence 
of PBMCs.  We used purified REIC/Dkk-3 protein to 
avoid the side-effects of adenovirus vector infection and 
focused on the antitumor effects of the protein itself.  
In this study,  purified REIC/Dkk-3 protein slightly 
reduced the proliferation of HCC tumor cells (Fig. 1).  
This effect was significantly enhanced in the presence of 
PBMCs; hence,  the REIC/Dkk-3 protein induced ther-
apeutic effects by activating PBMCs and thereby induc-
ing their anti-tumor activities.  Because the HCC tumor 
cells and PBMCs were derived from different donors,  
they expressed different types of major histocompatibil-
ity complex (MHC).  The REIC/Dkk-3 protein could 
induce an anti-tumor effect with PBMCs through an 
MHC-independent pathway.  A possible mechanism is 
cd1d-dependent natural killer T cell activation resulting 
in cytokine production [24].  Further study is necessary 
to elucidate this mechanism.
We previously reported the efficacy of adenovi-
rus-mediated REIC/Dkk-3 gene therapy in a mouse 
model of HCC [6].  The overexpression of the REIC/
Dkk-3 gene induced apoptosis in HCC cells.  The cur-
rent results revealed the anticancer effects of REIC/
Dkk-3 protein on HCC and the utility of combination 
therapy with the REIC/Dkk-3 protein and PBMCs in the 
treatment of HCC.  
Based on the above,  we focused on whether the 
serum REIC/Dkk-3 protein level could be used as a new 
prognostic biomarker in HCC patients.  The signifi-
cance of serum REIC/Dkk-3 protein levels was evalu-
ated in a previous study.  Kim et al.  reported on the 
combination of insulin-like growth factor binding pro-
tein 2,  pyruvate kinase M2,  and Dkk-3,  as a diagnostic 
panel for colorectal cancer.  Even in HCC,  Erdal et al.  
reported that the combination of Dkk-1 and AFP 
achieved better diagnostic results than AFP alone,  and 
that AFP was superior to Dkk-1 and Dkk-3 when used 
individually [25 , 26].  They evaluated the utility of the 
serum REIC/Dkk-3 protein level as a diagnostic marker 
for HCC and concluded that it was not suitable.  Thus,  
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REIC/Dkk-3 protein p-valueHigh (n=97) Low (n=97)
Age†(year) 73.76 74.04 0.85
Sex
Male 74 (54%) 64 (46%)
0.11Female 23 (41%) 33 (59%)
HBs Ag
(＋) 21 (53%) 19 (47%)
0.69(－) 76 (49%) 78 (51%)
HCV Ab
(＋) 59 (49%) 63 (51%)
0.61(－) 38 (53%) 34 (47%)
Alcohol consumption†(g)　　　※missing value: 82
41.9 34.7 0.52
TNM stage
I, II 86 (50%) 86 (50%)
0.15III, IV 11 (50%) 11 (50%)
Child-Pugh grade
A 91 (51%) 89 (49%)
0.34B or C  6 (43%)  8 (57%)
Initial treatment
Liver resecetion 39 (67%) 19 (33%) 0.001RFA therapy 58 (43%) 78 (57%)
we retrospectively investigated the serum REIC/Dkk-3 
protein levels of 194 HCC patients.  As shown in Fig. 2a,  
the 3-year disease-free survival rate of the REIC/Dkk-3 
high group was significantly higher than that of the 
REIC/Dkk-3 low group.  The 3-year overall survival rate 
of the REIC/Dkk-3 high group was also higher than that 
of the REIC/Dkk-3 low group; however,  the result was 
not statistically significant.  These data suggest that 
REIC/Dkk-3 protein acts as a tumor suppressor in 
human HCC.  
Our results suggested a possible beneficial anti-tumor 
effect of REIC/Dkk-3.  We therefore evaluated the utility 
of serum REIC/Dkk-3 protein levels as a prognostic 
marker for HCC patients,  and found that high-REIC/
Dkk-3 protein levels were associated with a fair prognosis.  
Our study also indicates that the REIC/Dkk-3 protein 
represents a useful mediator of antitumor immunity for 
HCC.  Although further analysis is necessary to eluci-
date the exact mechanisms of the interaction between 
the REIC/Dkk-3 protein and immune cells,  the immu-
nomodulatory effects of combined treatment tend to be 
observed in locally treated tumor lesions following ade-
novirus-mediated REIC/Dkk-3 gene therapy.  
Finally,  we should note that this study has some 
limitations due to its retrospective design.  First,  our 
population had an uneven background.  As many as 
40% of patients in the REIC/Dkk-3 high group under-
went curative surgical treatment,  compared to 20% of 
patients in the REIC/Dkk-3 low group.  In contrast,  
80% of patients in the REIC/Dkk-3 low group under-
went RFA therapy.  Many meta-analyses and RCTs have 
compared hepatectomy with RFA,  but whether RFA or 
hepatectomy is better remains controversial [27-29].  
Thus,  the prognostic difference caused by the therapeu-
tic modalities might have affected the survival analysis.  
Second,  hepatectomy was performed in 4 patients with 
portal vein tumor thrombosis (HCC Stage IV).  Those 
patients were all assigned to the REIC/Dkk-3 low 
group,  which might have affected the disease-free and 
overall survival rates.  Finally,  this study did not docu-
ment the treatments performed after primary therapy.  
Thus,  further prospective studies with well-defined and 
stratified patient populations are needed.
In conclusion,  this was the first study on the rela-
tionship between the HCC patient survival and serum 
REIC/Dkk-3 protein level in a large population.  Based 
on the results,  the serum REIC/Dkk-3 protein level 
should be considered a new prognostic marker for 
patients with HCC.
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